Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

Published:2022-01 Issue:1 Volume:7 Page:38-48
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Hu Huabin,Kang Liang,Zhang Jianwei,Wu Zehua,Wang Hui,Huang Meijin,Lan Ping,Wu Xiaojian,Wang Chao,Cao Wuteng,Hu Jiancong,Huang Yan,Huang Liang,Wang Huaiming,Shi Lishuo,Cai Yue,Shen Cailu,Ling Jiayu,Xie Xiaoyu,Cai Yonghua,He Xiaowen,Dou Ruoxu,Zhou Jiaming,Ma Tenghui,Zhang Xingwei,Luo Shuangling,Deng Weihao,Ling Li,Liu Hao,Deng Yanhong

Funder

National Natural Science Foundation of China

Ministry of Science and Technology of the People's Republic of China

Chinese Society of Clinical Oncology

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference40 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Microsatellite instability in colorectal cancer;Boland;Gastroenterology,2010

3. Pathways of colorectal carcinogenesis;Nguyen;Gastroenterology,2020